Alphabet spinoff Isomorphic Labs seeks funding at forty billion dollar valuation

Isomorphic Labs Limited is negotiating a new funding round to raise capital, Bloomberg reported. Bloomberg, Yahoo Finance, Proactive Financial News, TradingView, and SiliconANGLE all reported that the company is aiming for a valuation of at least 40 billion dollars, with SiliconANGLE noting the target valuation could reach up to 50 billion dollars. The specific size of the proposed investment deal was not disclosed. [1][2][3][4][5][6]

The British artificial intelligence company is based in London, England. Demis Hassabis, who previously co-founded DeepMind, founded Isomorphic Labs in 2021 as an Alphabet Inc. spinoff and currently serves as chief executive officer. The company operates as a digital drug discovery venture. [1][7][9]

The company relies on computational artificial intelligence models to simulate biological processes and design novel small-molecule therapeutics, building upon DeepMind's AlphaFold protein structure prediction system. In February 2026, Isomorphic Labs launched the Isomorphic Labs Drug Design Engine, an artificial intelligence platform known as IsoDDE. SiliconANGLE and Grokipedia noted that the software automates binding pocket discovery and improves binding affinity estimation, outperforming AlphaFold 3 in core benchmark metrics. [1][9]